JAZZ

Jazz Pharmaceuticals plc

119.12 USD
-10.58 (-8.16%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Jazz Pharmaceuticals plc stock is down -5.13% since 30 days ago. The next earnings date is May 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 52.94% of the previous 16 February’s closed higher than January. In the last 9 Unusual Options Trades, there were 3 PUTs, 6 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
02 Jan 19:28 15 Mar, 2024 145.00 PUT 30 0
05 Jan 18:13 19 Jan, 2024 135.00 CALL 100 496
09 Jan 20:36 20 Dec, 2024 120.00 PUT 50 268
12 Jan 19:08 15 Mar, 2024 120.00 CALL 150 49
12 Jan 19:09 15 Mar, 2024 120.00 CALL 250 49
12 Jan 19:26 15 Mar, 2024 120.00 CALL 596 49
20 Feb 14:50 15 Mar, 2024 120.00 CALL 25 1073
29 Feb 14:31 20 Dec, 2024 100.00 CALL 10 1
29 Feb 18:31 21 Jun, 2024 120.00 PUT 100 21

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc identifies, develops, commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi, Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the. treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for. adults with newly-diagn